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Abstract
The Steering Committee for the Prevention and Control of Infectious Diseases in Asia recently con-
ducted a survey of primary-care physicians in Asia, which revealed that many physicians administer
boosters in their clinical practice and that there is considerable variation and uncertainty among phy-
sicians regarding this practice. This paper serves as a response to physicians’ uncertainties by reviewing
the literature regarding the administration of hepatitis B vaccine boosters in high endemicity areas and
presenting the Steering Committee’s guidelines for booster administration. While there are few data to
support a need for routine hepatitis B vaccine boosters as a public health measure, they help to provide
reassurance of immunity against breakthrough infection in certain risk groups. In clinical practice,
primary-care physicians must exercise their judgment regarding the need for booster vaccination on an
individual basis. This paper examines the available literature on the administration and value of hepatitis
B vaccine boosters, explores the differences between the public health approach and clinical practice,
and provides guidelines for those who use boosters in high endemicity Asian populations. Relevant arti-
cles were identified through searches of MEDLINE (1975–2003) and the Cochrane Library, using ‘hep-
atitis B’ and ‘booster’ as primary search terms. Guidelines for those who decide to administer hepatitis
B vaccine boosters include: boosting approximately 10–15 years after primary vaccination; boosting
rather than not when monitoring of antibody levels is not feasible; boosting immunocompromised
patients when the antibody to hepatitis B surface antigen titer falls below 10 mIU/mL; and boosting
healthcare workers based on the endemicity of the particular country.
© 2004 Blackwell Publishing Asia Pty Ltd
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INTRODUCTION
The Steering Committee for the Prevention and Con-
trol of Infectious Diseases in Asia meets biannually to
discuss the latest research and clinical trends in infec-
tious disease prevention and control. This review was
written in response to a survey conducted by the Steer-
ing Committee of primary-care physicians in Asia,
which showed considerable variation and uncertainty of
opinion regarding the administration of hepatitis B vac-
cine boosters, despite many physicians administering
boosters in their clinical practice.
The protective efficacy of a primary course of hepa-
titis B vaccine is well established. Long-term protection
against clinically significant breakthrough hepatitis B
virus (HBV) infection and chronic carriage depends on
immunological memory, which appears to last at least
10–15 years in immunocompetent individuals who
respond adequately to the primary vaccination.1–3 Per-
sisting antibodies to hepatitis B surface antigen (anti-
HBs)4 and/or in vitro B-cell stimulation response,5 or an
anamnestic response to a vaccine challenge,2 provide
evidence of adequate immunological memory in these
individuals.
While there are few data to support a need for routine
hepatitis B vaccine boosters in immunocompetent indi-
viduals who have responded to a primary course,6,7
boosters are recommended and widely used to provide
reassurance of protective immunity against break-
through infection in certain risk groups. For example,
advisory bodies in some countries state that healthcare
workers should have their anti-HBs response measured
following primary vaccination, and that their antibody
levels should be monitored at regular intervals.8–10
Booster immunization should be administered to any
individual who is found to be inadequately protected
(generally defined as an anti-HBs level <10 mIU/mL,4).
Administration of these boosters will help to protect
healthcare workers from the risk of infection when
repeatedly exposed to HBV through contact with
patients.
Other high-risk groups include persons with compro-
mised immunity, such as hemodialysis and renal trans-
plant patients,11,12 leukemia patients,13 and individuals
with chronic hepatitis C.14 Some populations are at
increased risk as a result of high rates of at-risk behav-
ior, such as adolescents,15 homosexual men4 and prison
inmates.16 Close contacts of HBV carriers are also at
increased risk.4 In immunocompromised individuals,
monitoring of anti-HBs blood levels and hepatitis B
vaccine boosters are currently recommended.6 In other
high-risk groups, primary vaccination is the main
priority.4,6
In the general population, there is no apparent need
for hepatitis B vaccine boosters in national immuniza-
tion programs as a public health measure, particularly
in the low endemicity areas of Europe, where the like-
lihood of exposure to HBV is low.7,17 However, in high
endemicity countries the risk of exposure is not only
high, but also recurrent,18 which is why we revisit the
issue of the need for booster vaccination. It is here that
physicians need to exercise their clinical judgment on an
individual basis.
CURRENT PUBLIC HEALTH 
RECOMMENDATIONS
In 1991, the World Health Organization (WHO) rec-
ommended that the hepatitis B vaccine be integrated
into all national immunization programs. As a result,
many nations have implemented universal infant immu-
nization with or without adolescent immunization.19
In Asia, the WHO recommendations have, to a large
extent, been implemented, and effective vaccination
programs have resulted in a shift in endemicity in some
countries. While China continues to experience high
HBV endemicity, countries with intermediate endemic-
ity include India, Korea, the Philippines, Taiwan and
Thailand.18 Japan, Pakistan, Bangladesh, Singapore, Sri
Lanka and Malaysia all have low endemicity.18 In high
endemicity areas primary vaccination remains the top
priority public health measure against hepatitis B.
Most health advisory bodies are based in low ende-
micity regions such as Europe and North America.
They currently stress the need for primary vaccination
against hepatitis B, suggesting that routine boosting is
not required, except in immunocompromised individu-
als, such as those with HIV infection or chronic renal
disease (Table 1).4,6,20,21 Booster doses may be needed in
these individuals to avoid infection, disease, or the car-
rier status that may result from infection.20 According
to the Canadian National Advisory Committee on
Immunization (NACI) guidelines, the optimal timing
of booster doses in immunocompromised patients is
unknown, so they recommend that the timing of boost-
ers should be based on the severity of the compromised
state and the results of regular monitoring.20
The European Consensus Group conclude that there
is little available evidence to support the use of hepatitis
B vaccine boosters in other high-risk groups, such as
intravenous drug users, persons who engage in high-risk
sexual behavior, residents of mental institutions, close
contacts of hepatitis B surface antigen (HBsAg) carriers
and immigrants to Europe.6
For low-risk individuals, the NACI and the US
Immunization Practices Advisory Committee (ACIP)
state that further investigation into the duration of the
protective immunity in adolescents who were vacci-
nated against hepatitis B during infancy or childhood is
necessary. The results of further research will determine
future recommendations concerning booster doses for
immunocompetent individuals.4,20
NON-RESPONDERS
Research in Europe and the USA has demonstrated that
subjects who appear unresponsive or minimally respon-
sive to the primary three-dose hepatitis B vaccination
account for 5–15% of vaccinees.22,23 However, these
individuals are not necessarily absolute non-responders:
the majority can develop protective levels of anti-HBs
after additional hepatitis B vaccination, consisting of a
fourth or fifth dose, or an additional complete course of
vaccination.21,24,25 Administration of these additional
doses of vaccine to low-level or non-responders can, in
most cases, result in adequate antibody response and
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immunological priming.6 This approach is therefore
recommended for individuals who do not respond well
to a primary course, to ensure that they eventually
achieve antibody levels >10 mIU/mL.6
In a routine immunization program it is neither
recommended nor feasible to test the postvaccination
antibody response and titer. Therefore low-level and
non-responders will not be identified. While 90–95%
seroconversion may be acceptable in a national immu-
nization program, 100% seroconversion may be the
goal in clinical practice. Thus, variations from the vac-
cination schedule may need to be accommodated to
achieve clinical goals.
LONG-TERM ANAMNESTIC 
ANTIBODY RESPONSE
In clinical studies conducted in Taiwan and Thailand,
a primary course of hepatitis B vaccination has
been shown to result in protective levels of antibody
(>10 mIU/mL) in the great majority of vaccinees (83–
99%).1,26 However, the proportion of vaccinees with
protective levels of antibody decreases to 75–87% after
5 years and to 50–70% after 10–12 years.1,26
Despite anti-HBs levels falling to <10 mIU/mL, data
presented in a number of studies suggest that immuno-
logical memory continues to provide effective protec-
tion from hepatitis B disease (although not necessarily
from infection).1,2,27–31 This implies that, in the majority
of individuals, booster vaccination is unnecessary at
least until, or even beyond, 5–10 years following the pri-
mary vaccination series.
Huang et al. studied the children of hepatitis B e
antigen-positive/HBsAg-carrier mothers in Taiwan, and
found that the hepatitis B vaccine protected them to at
least 10 years of age.1 Immunologic memory was
detected in all subjects, including those with anti-HBs
titers <10 mIU/mL, when boosters were administered
at 10 years of age.
Studies that have followed subjects for more than
10 years postvaccination have reported mixed results.
In observational studies, protection against chronic car-
riage of hepatitis B has been reported to last up to 13–
16 years postvaccination.32–35 In randomized controlled
trials, the rate of chronic carriage between 10 and
15 years postvaccination was found to be low (0.3% in
one study and 0% in another),36,37 and was significantly
different from placebo in one study (0.3% vs 8.2%),36
but not in another (0% vs 0%).37
West and Calandra reviewed studies on the persis-
tence of immunological memory in vaccinated, healthy
populations in Italy, Switzerland, the USA, New
Zealand, Spain and Taiwan.2 Few clinically significant
breakthrough infections were found even in populations
at high risk of exposure to HBV. They suggested that
immunosuppressed patients may be the only subgroup
in which it is necessary to maintain antibody levels
>10 mIU/mL. In the case of healthy, immunocompe-
tent vaccinees, the available choices are either not to
boost and expect a small number of cases of infection
to occur, to boost using a single lifetime booster, or to
administer multiple boosters at intervals of 10 years.
Banatvala and Van Damme conducted a similar
review looking at the European and worldwide litera-
ture on the persistence of immunity to hepatitis B.7
They concluded that protection against HBV break-
through infection is dependent on immune memory
rather than anti-HBs levels. Therefore they agreed with
the European Consensus recommendations that hepa-
titis B vaccine boosters appear to be unnecessary in
immunocompetent individuals following completion of
a primary course of vaccination. The authors point out,
however, that long-term studies are needed to deter-
mine whether vaccinees develop breakthrough infection
or the carrier state at a later stage.
In summary, for the vast majority of individuals
receiving hepatitis B vaccine, protection from disease,
but not necessarily infection, is present for more than
10 years. The absolute length of protection is yet to be
determined.
Table 1 Booster recommendations in North America and Europe
Advisory body Recommendations
ACIP and CDC
(USA)4,20
Boosters are not recommended for children or adults with normal immune status
Post-vaccination testing should be considered for persons at occupational risk of hepatitis B virus 
infection (who may be exposed to the virus through needle-stick injury). Testing should take place 
1–3 months after vaccination
For hemodialysis patients, monitor antibody levels annually and administer a booster if levels fall below 
10 mIU/mL
NACI (Canada)20 Boosters are not recommended for children or adults with normal immune status (including healthcare 
workers)
For immunologically compromised patients, monitor antibody levels annually.
ECG (Europe)6 Boosters are not recommended for children or adults with normal immune status (including healthcare 
workers)
Use boosters to maintain anti-HBs levels above 10 mIU/mL in immunocompromised individuals
Post-vaccination testing every 6–12 months is advisable in immunocompromised patients.
ACIP, Immunization Practices Advisory Committee; CDC, Centers for Diseases Control and Prevention; ECG, European
Consensus Group; NACI, National Advisory Committee on Immunization.
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NATURAL BOOSTING
There is some evidence that a natural boosting effect
may occur from exposure to individuals with HBV, and
that this is a mechanism for long-term protection
against the disease in areas of high HBV endemicity.38–
40 Several studies have been conducted in high ende-
micity areas looking at children who were immunized at
birth to see how many of these children have subse-
quently developed HBV infection.39,41,42
In Chinese41 and Taiwanese42 studies, the rate of
acquisition of antibody to hepatitis B core antigen (anti-
HBc) was approximately 1–2% per annum, but in no
case did HBsAg develop and no clinical events occurred
in any of these children. In a study of Senegalese infants
immunized against hepatitis B at birth, 20% developed
anti-HBc antibodies and serum HBsAg was detected in
2.2%.39 No difference was observed in HBsAg detection
between infants who received a booster dose at school
age (one of 41 children) and those who did not (one of
51 children).
The significance of anti-HBc development is not
clear. There is some concern that low level anti-HBs
may make the individual more likely to develop vaccine
escape variant viruses.43 There is also some evidence
that patients with hepatitis C and anti-HBc are at
greater risk of development of occult hepatitis B infec-
tion,44 which can contribute to the development of
hepatocellular carcinoma (HCC); however, prospective
studies are needed to allocate risks.
BOOSTER VACCINATIONS
Based on recommendations in Europe and the
USA,4,6,21 and taking into account the current state of
knowledge, hepatitis B booster vaccination can only be
firmly recommended for low-level and non-responders,
particularly healthcare workers, those in other high-risk
professions and the immunocompromised, living in
Asia. However, key differences exist between conditions
in Asia and those in North America and Europe. The
higher endemicity of hepatitis B in Asia results in an
increased likelihood of non-protected individuals being
exposed to HBV at some stage in their life compared
with the average risk of exposure for individuals in
North America or Europe.
Hepatitis B virus infection in early childhood is the
main cause of chronic HBV status in Asia, and universal
vaccination of all infants is therefore the most effective
method of control.45 In high and intermediate endemic-
ity countries, prevention of transmission of hepatitis B
infection from HBsAg-positive mothers to infants is
critical for decreasing both the hepatitis B carrier pool
and the associated morbidity and mortality caused by
chronic infection. However, implementation of such a
universal primary vaccination program remains a major
challenge in much of Asia.45 Routine screening of all
pregnant women is not feasible in many countries43 and
therefore vaccination of all newborns is necessary to
prevent vertical transmission. However, this is problem-
atic in areas where contact with immunization services
may not be possible at the time of delivery.
Because of these differences between conditions in
Asia and those in Europe and North America, a differ-
ent approach to hepatitis B prevention and control may
be warranted in each respective region, even in national
immunization programs for public health. There are
also a number of situations in which public health rec-
ommendations and the needs of the individual may not
correspond (Table 2). In these situations, physicians
should administer boosters at their own discretion. The
Steering Committee for the Prevention and Control of
Infectious Diseases in Asia have put forward guidelines
for physicians in high endemicity areas who choose to
administer hepatitis B vaccine boosters (Table 3).
CONCLUSIONS
The use of hepatitis B vaccine has been highly success-
ful in preventing the development of chronic hepatitis B
Table 2 Occasions where public health recommendations
and the needs of individuals may not correspond
Inadequate provision of primary immunization means that a 
small percentage of the population will miss out
Vaccine failure as a result of delivery problems or non-
responders
Waning immunity with age or because of disease in 
immunocompromised patients
Occupational risk in healthcare workers
Viral factors (i.e. exposure to high viral titers)
Importance of low-level infection
Table 3 Hepatitis B vaccine booster guidelines, 2003
Widespread primary vaccination should be the top priority in 
Asia. Where there are concerns about a highly increased risk 
of infection, and immunity from primary vaccination is 
thought to be substandard, physicians should exercise their 
own clinical judgment on a case-by-case basis
Where administration of a booster vaccine is considered 
necessary, it should take place approximately 10–15 years 
after primary vaccination. For children vaccinated as infants 
this may be particularly important, as this is around the age 
when at-risk behaviour often begins
Where monitoring of antibody levels is not feasible, it is better 
to administer a booster than not. Again, physicians must use 
their own judgment in these cases
Boosting of immunocompromised persons should take place 
when antibody levels drop below 10 mIU/mL
Administering boosters to healthcare workers should be a 
selective decision, depending on the endemicity of the 
particular country in question. Despite the cost of boosting 
and the potential inconvenience, employers of healthcare 
workers have a responsibility to ensure staff are adequately 
protected. This may be done through routine anti-HBs 
assessment and boosters when necessary, or routine regular 
boosters without assessing antibody levels
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and HCC in Asia and other areas of high hepatitis B
endemicity.18,19 Universal vaccination of infants is the
top priority for hepatitis B control in Asia.
After successful vaccination against hepatitis B infec-
tion, immunity persists for at least 10 years in the
majority of individuals, and routine booster administra-
tion is not currently recommended as a public health
measure. However, there will always be circumstances
in which the recommendations for an individual lie out-
side the recommendations for a population, and it is the
role of the physician to offer his/her patient the best of
care. In regions of Asia where hepatitis B is highly
endemic, vaccine boosters may help to ensure
immunity.
The Steering Committee for the Prevention and
Control of Infectious Diseases in Asia have developed
guidelines for physicians who choose to administer
hepatitis B vaccine boosters in Asia, including: timing
booster administration at approximately 10–15 years
after primary vaccination; to boost rather than not
when monitoring antibody levels is not feasible; to
boost immunocompromised patients when the anti-
HBs titer falls <10 mIU/mL; and to boost healthcare
workers based on the endemicity of the particular
country.
The question of whether widespread booster immu-
nization against hepatitis B will be necessary at a later
age, such as at 15 or 20 years, even in national immu-
nization programs, requires further study,4,6,7,20,32 and
these studies are likely to be carried out in Asia.
Future research needs to concentrate on the follow-
ing areas in order to learn more about the duration of
immunological memory and thus help determine the
best use of vaccine resources. Long-term data on the
efficacy of the hepatitis B vaccine in non-responders
need to be acquired.21,24 The issue of postvaccination
testing, and whether it should it be restricted to high-
risk subjects, needs to be addressed, and more long-
term monitoring is required to confirm the absence of
clinically significant breakthrough infections in vacci-
nated groups up to the 10–15-year threshold.1,4,6,7,20
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